UBS Group
ALDX icon

UBS Group’s Aldeyra Therapeutics ALDX Stock Holding History

UBS Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,000
Closed -$80K – 10186
2021
Q4 		$80K Buy
+20,000
New +$153K ﹤0.01% 6500

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

UBS Group's ALDX Position: Q2 2026 in Review

UBS Group reduced its Aldeyra Therapeutics (ALDX) stake by 44% in Q2 2026, selling an estimated $405K and leaving 301,940 shares worth $643K. The position accounts for ﹤0.01% of the portfolio, ranked #6079.

UBS Group first reported a position in ALDX in Q1 2015 and has held it in 43 quarters since. The position peaked at $4.27M in Q1 2022. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • UBS Group held 301,940 shares of Aldeyra Therapeutics worth $643K as of Q2 2026.
  • UBS Group sold 235,629 Aldeyra Therapeutics shares in Q2 2026, an estimated $405K.
  • Aldeyra Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6079 holding.
  • UBS Group first reported a position in Aldeyra Therapeutics in Q1 2015 and has held it in 43 quarters since.
  • UBS Group's Aldeyra Therapeutics position peaked at $4.27M in Q1 2022.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.